Á lódáil...
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estimated to be approaching 200 million people(1). Current therapy relies upon a combination of pegylated interferon-α and ribavirin, a poorly tolerated regimen typically associated with less than 50% sustained virological resp...
Na minha lista:
| Foilsithe in: | Nature |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
Nature Publishing Group UK
2010
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7094952/ https://ncbi.nlm.nih.gov/pubmed/20410884 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature08960 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|